Latest Information Update: 30 Aug 2002
At a glance
- Originator Novartis
- Class Antineoplastics; Antisense oligonucleotides
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 22 Jun 1999 Phase-II clinical trials for Solid tumours in USA (IV)